Table 1.
Baseline clinical and demographic characteristics of patients.
| Parameter | CMD+ n = 47 |
CMD− n = 73 |
p-Value |
|---|---|---|---|
| Age, years | 61 (56; 68.5) | 61.5 (59; 67.5) | 0.123 |
| Male sex, n (%) | 26 (57.8) | 44 (60.3) | 0.901 |
| Body mass index, kg/m2 | 29.9 (27.8; 31.9) | 30.2 (27.9; 32.1) | 0.276 |
| Hypertension, n (%) | 37 (82.2) | 46 (63.0) | 0.069 |
| Type 2 diabetes mellitus, n (%) | 11 (24.4) | 6 (8.2) | 0.007 |
| History of COVID-19, n (%) | 7 (15.6) | 12 (16.4) | 0.318 |
| COPD, n (%) | 7 (15.6) | 13 (17.8) | 0.723 |
| Paroxysmal AF, n (%) | 7 (15.6) | 11 (15.1) | 0.769 |
| HFpEF, n (%) | 34 (75.6) | 24 (32.9) | <0.001 |
| Smokers, n (%) | 11 (24.4) | 5 (6.8) | 0.009 |
| eGFR (mL/min/1.73 m2) | 77.2 (63.2; 81.2) | 77.0 (64.0; 85.0) | 0.543 |
| Total cholesterol, mmol/L | 4.635 (3.67; 5.25) | 4.33 (3.54; 4.98) | 0.898 |
| LDL-C, mmol/L | 3.12 (2.15; 3.51) | 2.87 (2.25; 3.87) | 0.456 |
| HDL-C, mmol/L | 1.05 (0.83; 1.32) | 1.05 (0.96; 1.26) | 0.887 |
| Triglyceride, mmol/L | 1.67 (1.23; 1.89) | 1.59 (1.22; 1.86) | 0.835 |
| Hemoglobin, g/dL | 134 (121; 143) | 137 (128; 142) | 0.464 |
| Potassium, mmol/L | 4.64 (4.12; 5.01) | 4.81 (4.43; 5.21) | 0.517 |
| Fibrinogen, g/L | 3.27 (3.14; 3.14) | 3.10 (2.86; 3.43) | 0.767 |
| HbA1c, % | 5.9 (5.1; 6.9) | 5.8 (5.1; 6.4) | 0.098 |
| β-blockers, n (%) | 8 (17.8) | 10 (13.7) | 0.876 |
| ACE inhibitors/ARBs, n (%) | 5 (11.1) | 9 (12.0) | 0.879 |
| Diuretics, n (%) | 3 (6.7) | 8 (10.9) | 0.546 |
| Statins, n (%) | 8 (17.8) | 15 (20.5) | 0.547 |
| Amiodarone, n (%) | 2 (4.4) | 5 (6.8) | 0.358 |
| ARA, n (%) | 2 (4.4) | 4 (5.5) | 0.269 |
Note. CMD—Coronary microvascular dysfunction; COVID-19—Coronavirus disease 2019; COPD—Chronic obstructive pulmonary disease; HFpEF—Heart failure with preserved ejection fraction; eGFR—Estimated glomerular filtration rate; LDL-C—Low-Density Lipoprotein Cholesterol; HDL-C—High-Density Lipoprotein Cholesterol; HbA1c—Glycated hemoglobin; ACE—Angiotensin-converting enzyme inhibitors; ARBs—Angiotensin II receptor blockers; ARA—Aldosterone receptor antagonists.